Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Heart Failure with Reduced Ejection Fraction
NCT07697833Phase 4Not yet recruiting
- Sponsor
- National Institute of Cardiovascular Diseases
- Start
- Jul 2026
- Primary completion
- May 2027
01
Overview
Phase 4, randomised, double-blind trial of Vericiguat oral suspension (Formulation 4) in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by National Institute of Cardiovascular Diseases. Primary endpoint: Kansas City Cardiomyopathy Questionnaire at 6 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07697833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697833.